[December 11, 2017] |
|
TransMed7, LLC Announces Inaugural Members of its Business Advisory Board
TransMed7, LLC today announced the creation of and inaugural
appointments to its Business Advisory Board (BAB). The TransMed7 BAB is
composed of accomplished business experts offering innovative advice and
dynamic perspectives that will contribute to the accomplishment of
TransMed7's tactical goals and strategic objectives. These experts
represent a carefully selected group of proven innovators, each of whom
has already established his or her reputation based on high ethical
standards, demonstrated leadership, and a willingness to embrace and
support a mission for the good of others. The Members of the BAB provide
TransMed7's Senior Management Team with expanded business perspectives
in a constantly changing environment, and each Member brings a focus and
particular emphasis on one or more of a number of business sectors,
including but not limited to the following areas:
-
Strategic Planning, including Tactical Execution;
-
Commercial Launch of new Platform Technologies;
-
U.S. and O.U.S.-based Distributors and Sales Networks;
-
Corporate Relations Analysis and Development;
-
International Business Management and Strategic Market Development;
-
Financial Management, Fundraising and Investment Performance Options;
-
Corporate Compliance and Tax Planning Advice; and
-
Public Relations, Networking, Communications and Advocacy.
"We are honored to have these internationally recognized leaders as the
founding members of our Business Advisory Board," commented Eugene H.
Vetter, TransMed7 CEO and Chairman of the BAB. "In addition to their
individual business perspectives, they bring additional experience as
founders, inventors, and entrepreneurs to our organization and will be
integral to TransMed7's commercial launch of our critically needed,
minimally-invasive medical technologies to get them into the hands of
clinicians for the benefit of their patients around the world as rapidly
as possible."
The inaugural members include:
Tony Astorga - Mr. Astorga actively serves on several both public
and private boards including his current position as Chairman of the
Board at the Arizona Hispanic Chamber of Commerce Foundation. He also
serves as a financial consultant to AZTOR Health and Wealth Management
Advisors. Mr. Astorga formerly served as Senior Vice President, CFO, and
Chief Business Development Officer for Blue Cross Blue Shield (BCBS) of
Arizona as well as the President of BCBS of Mexico. A graduate of
Arizona State University with a Bachelor in Accounting, Mr. Astorga is a
CPA and former founding partner of Astorga and Maurseth, Certified
Public Accountants.
Mark Bradley - Most recently Mr. Bradley served as CEO and Board
Member of Conversica; one of the fastest growing artificial intelligence
companies in the world. He currently serves on several boards in the
tecnology and education sectors including the Southern Methodist
University (SMU) Lyle School of Engineering. Prior to this, Mr. Bradley
was a Co-Founder, President, and Senior Vice President of Global Product
Shopping/International/Operations of NexTag, known for its popular
consumer website providing price comparison shopping information and
which exited in 2007 for $1.3B after opening successful operations in 9
countries. Mr. Bradley is a graduate of Southern Methodist University
with a Bachelor in Finance.
Carlos Collazo - Starting from his facilitating creation of the
current Standard International Trade Commodity Classification System,
Mr. Collazo has leveraged his expertise to found and/or lead several
successful technology companies. These include Mariner Systems
Incorporated (MARSYS) where he was the Founder, CEO, and Chairman until
it was sold in 2013. The MARSYS Group of companies consisted of
associated companies in the information technology and services industry
and delivered technology services to Fortune 500 companies in over 20
countries for more than 30 years. The derivative works from the core
technologies developed under Mr. Collazo's leadership are still in
productive use in the market via licenses and/or acquisitions and
include applications to cyber security, systems optimization, digital
media, data analytics, education, trade systems and others. Mr. Collazo
has served on the boards of several educational institutions and
leadership councils including Notre Dame University and the Cyber
Intelligence Initiative. He is a graduate of Oklahoma State University.
Thomas Cowan - Mr. Cowan is Director of The Center for Technology
Management at Columbia University and most recently served as CEO at
modomodo, a SaaS (News - Alert) mobile application development platform company. Mr.
Cowan is recognized as a technology CEO and entrepreneur creating value
through execution with particular expertise in enterprise software, Big
Data analytics, and SaaS delivery. He spent more than two decades at IBM (News - Alert)
starting in Finance and moving to CFO and GM roles. He subsequently
served as Chairman and CEO of OutlookSoft, a leading developer of
business performance software, and positioned the company for its
acquisition by SAP (News - Alert). At Vcommerce, a pioneer developer of e-commerce
software, Mr. Cowan served as Chairman/CEO/COO/CFO where he led a
successful restructuring which established the basis for later
acquisition by Google (News - Alert). Mr. Cowan has served on numerous public and
private boards including SMTC Corporation, Wake Forest University, and
Tivoli Systems. He is the author of From Idea to Business, Business
Basics, and Leadership Basics. He received his Bachelor in Economics
from Wake Forest University and an MBA from the University of South
Carolina.
"Each of the inaugural members of our BAB bring years of successful
experience across many of the important industries related to and
supportive of TransMed7's mission ("to efficiently design, develop, and
deliver transformational, minimal access medical devices which address
patient needs from diagnosis to therapy")," said Dr. Edgar D. Staren,
President of TransMed7 and Executive Chairman of the BAB. "We are
grateful for their willingness to serve as BAB members and look forward
to benefitting from their judgment and counsel."
In anticipation of 510(k) clearance expected in the first quarter, 2018,
TransMed7 is finalizing production and market introduction strategies
for its SpeedBird™ soft tissue biopsy product platform and its Concorde™
platform technology for stereotactic and MRI based biopsy
procedures, with rollout for both domestic and international sales and
distribution. In addition, the BAB will provide crucial guidance as
TransMed7 continues development of its portfolio of next generation
products based on innovative variations of its patented "Zero5" working
element, which include: Cardinal™, a fine-needle core biopsy
device for breast, thyroid, and lymph nodes; and Cygnet™, a novel
device designed to establish continued access for intervention including
aspiration and biopsy of bone marrow. TransMed7 is also currently
developing Martinet™, a revolutionary new minimal access device
for complete removal of target tissue.
About TransMed7, LLC
TransMed7, LLC is a medical and technology based organization focused on
the highly efficient development of innovative, minimally invasive
medical devices aimed at providing new solutions for doctors and their
patients. With particular expertise in both oncologic, regenerative, and
cardiovascular disease, TransMed7 and its team of clinicians,
scientists, and engineers have developed a portfolio of next-generation
platform devices that are expected to be market leaders in their
targeted fields of medicine. TransMed7 accomplishes this through
application of a wholly new approach in its business plan and structure,
enabling these new transformational technologies from rapid development
through commercial manufacturing or where appropriate, handoff to our
Strategic Partners. For more information about TransMed7, please visit
our website at www.transmed7.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171210005137/en/
[ Back To Mobile World Congress's Homepage ]
|